Advancing Excellence in Peptide Research
3rd Party Tested in the USA
$59.95
ARA 290 is a synthetic peptide with potential neuroprotective and anti-inflammatory effects, primarily studied for its applications in diabetic neuropathy. Its benefits include improving nerve function, reducing inflammation, and preserving nerve health. While generally safe based on preliminary studies, individuals should consult healthcare professionals for personalized advice on dosing, administration, and monitoring during treatment. ARA 290 is currently in the clinical trial phase and has yet to receive regulatory approval for routine clinical use.
History/Background:
ARA 290, also known as an adrenergic receptor agonist, is a synthetic peptide derived from a human peptide. It was developed to target various signaling pathways involved in neuroprotection and tissue repair. ARA 290 is believed to have roles in reducing inflammation and promoting cell survival, particularly in tissues affected by diabetes and related complications. ARA 290 has been studied for its potential therapeutic applications in neuropathies, particularly diabetic neuropathy, and other conditions where nerve health and function are compromised.
Research For:
The potential benefits of ARA 290 include:
Neuroprotective Effects: ARA 290 has been shown to exert neuroprotective effects, potentially preserving nerve function and preventing degeneration in diabetic neuropathy.
Anti-Inflammatory Properties: The peptide may help reduce inflammation, which is particularly beneficial in conditions associated with chronic inflammation, such as diabetes.
Improved Nerve Function: Research indicates that ARA 290 may enhance nerve function and improve symptoms associated with neuropathy, including pain, tingling, and numbness.
Potential Applications Beyond Neuropathy: While primarily studied for diabetic neuropathy, ARA 290 may have broader applications in other neurodegenerative conditions and metabolic disorders.
Important Considerations:
Regulatory Status: ARA 290 is still undergoing clinical development and has not yet received FDA approval for widespread clinical use. Its availability may be limited to clinical trials or specific research settings.
Side Effects: ARA 290 is generally considered safe in clinical studies, but potential side effects may include injection site reactions, headaches, and gastrointestinal discomfort.
Individual Variability: Responses to ARA 290 can vary among individuals, influenced by factors such as the severity of neuropathy, overall health status, and concurrent medications.
Consultation with Healthcare Professionals: Patients should consult healthcare providers to determine the appropriate dosage and administration schedule tailored to their specific health conditions.
| Amount | 10mg |
|---|
Reviews
There are no reviews yet.